Illumina (NASDAQ:ILMN) today announced that the Genomic Medicine
Institute (GMI) at Seoul National University College of Medicine in
Korea, purchased seven additional Illumina Genome AnalyzerIIx
sequencing systems, expanding the capacity of their recently established
Asian Genome Center to 10 Illumina sequencing systems.
“GMI’s decision to add seven additional Genome Analyzers is further
validation that our sequencing platform is delivering leading
performance with its unmatched rate of daily output, ease of use and
proven paired-end sequencing capabilities,” said Tim Orpin, general
manager of Illumina’s Asia Pacific Region.
Dr. Jeong-Sun Seo, director of the Genomic Medicine Institute, and his
team, have completed a deep sequencing project of the Korean genome and
the work was published online in Nature July 8, 2009. “This
publication demonstrates the global competitiveness of GMI’s
technological capabilities and provides a practical example of Korean
bio-medical excellence,” said Dr. Seo.
GMI is the second largest Genome Center in Asia and the largest center
that focuses exclusively on human genome analysis and its clinical
application in Asia. As part of the Asian 100 Genome Project, GMI plans
to complete the whole genome analysis of 100 Asian individuals by 2012
and establish an Asian Genome Database with comprehensive genome
information specifically targeting Asian populations.
About the Illumina Genome Analyzer
Designed for facilities of all sizes, the Illumina Genome Analyzer has
been adopted across genome centers worldwide, plus individual research
labs, core and service facilities, and biotechnology and pharmaceutical
companies. Generating over 20 Gigabases of sequence data, the Genome
Analyzer offers the highest rate of daily output and the simplest and
most user-friendly workflow. The Genome Analyzer also offers the
broadest set of supported applications, including those used to profile
and discover novel transcripts, to create a high-resolution genome-wide
map of DNA-protein binding sites and to sequence entire human genomes to
greater than 30x coverage. For more information about the Genome
Analyzer and to read what customers are doing with Illumina's sequencing
technology, please visit http://www.illumina.com/sequencing.
About Illumina
Illumina (www.illumina.com)
is a leading developer, manufacturer, and marketer of next-generation
life-science tools and integrated systems for the analysis of genetic
variation and biological function.
